Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

Background: Poly (ADP-ribose) polymerase (PARP) inhibitor and antiangiogenic agent monotherapy have shown to be effective as maintenance treatment in patients with ovarian cancer (OC). However, there is currently a lack of evidence-based study to directly compare the effects of combination therapy w...

Full description

Bibliographic Details
Main Authors:	Yan Wei, Li He, Tao Liu, Tao Guo, Cong Xie, Jigang Jia, Yonghong Lin, Jiang Liu, Jiayin Fan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Pharmacology
Subjects:	PARP inhibitors antiangiogenic agents olaparib bevacizumab ovarian cancer combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1372077/full

Similar Items

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
by: Guojuan Sun, et al.
Published: (2024-09-01)

Modern aspects of antiangiogenic therapy in ovarian cancer
by: A. A. Rumyantsev, et al.
Published: (2018-11-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: An institutional case series and literature review
by: Yukari Tsuchino, et al.
Published: (2024-08-01)

Increase in serum creatinine levels after PARP inhibitor treatment
by: Di You, et al.
Published: (2023-12-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
by: Ignacio Romero, et al.
Published: (2024-01-01)

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
by: Youwen Zhu, et al.
Published: (2023-08-01)

First-line treatment of advanced ovarian cancer: an expert update
by: Branka Petrić-Miše
Published: (2020-01-01)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
by: Hongyu Qin, et al.
Published: (2023-01-01)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
by: Xiu Chen, et al.
Published: (2023-01-01)

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance
by: Yue Huiran, et al.
Published: (2023-04-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)

Never tear us a-PARP: Dealing with DNA lesions during mitosis
by: Pepijn M. Schoonen, et al.
Published: (2018-01-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
by: Tadahiro Shoji, et al.
Published: (2021-05-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
by: Yasushi Iida, et al.
Published: (2024-02-01)

Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature
by: Daniela Luvero, et al.
Published: (2024-06-01)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
by: Angela Dalia Ricci, et al.
Published: (2020-08-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Olaparib Conjugates with Selenopheno[3,2-<i>c</i>]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance
by: Marina Makrecka-Kuka, et al.
Published: (2022-11-01)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
by: Kamila Burdova, et al.
Published: (2019-10-01)

PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer
by: Mengqiu Huang, et al.
Published: (2023-07-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
by: Christoph Rogmans, et al.
Published: (2024-11-01)

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program
by: A. A. Rumyantsev, et al.
Published: (2022-06-01)

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
by: Shiue-Wei Lai, et al.
Published: (2020-04-01)

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations
by: N. A. Avxentyev, et al.
Published: (2021-10-01)

Olaparib-Resistant <i>BRCA2</i><sup>MUT</sup> Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
by: Łukasz Biegała, et al.
Published: (2023-03-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
by: István Baradács, et al.
Published: (2024-02-01)

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
by: Jing Ni, et al.
Published: (2020-03-01)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
by: Sidneia Sousa Santos, et al.
Published: (2022-06-01)

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy
by: ZANG Rongyu
Published: (2023-02-01)

Mechanism and rational combinations with GP‐2250, a novel oxathiazine derivative, in ovarian cancer
by: Mark S. Kim, et al.
Published: (2024-08-01)

Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: Huayi Li, et al.
Published: (2024-05-01)